BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11242595)

  • 1. Chronic myeloid disorders: Classification and treatment overview.
    Tefferi A
    Semin Hematol; 2001 Jan; 38(1 Suppl 2):1-4. PubMed ID: 11242595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
    Tefferi A
    Mayo Clin Proc; 1998 Dec; 73(12):1177-84. PubMed ID: 9868417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Mesa RA
    Int J Hematol; 2002 Aug; 76 Suppl 2():193-203. PubMed ID: 12430925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ; Thiele J
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
    Kreipe HH
    Veroff Pathol; 1993; 141():1-158. PubMed ID: 8372486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
    Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
    Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
    Bock O
    Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology of the myeloproliferative diseases.
    George TI; Arber DA
    Hematol Oncol Clin North Am; 2003 Oct; 17(5):1101-27. PubMed ID: 14560777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates.
    Yoon SY; Li CY; Tefferi A
    Eur J Haematol; 2000 Sep; 65(3):170-4. PubMed ID: 11007052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical myeloproliferative disorders: diagnosis and management.
    Tefferi A; Elliott MA; Pardanani A
    Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Planimetric analysis of megakaryocytes in the four main groups of chronic myeloproliferative disorders.
    Nafe R; Georgii A; Kaloutsi V; Fritsch RS; Choritz H
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1991; 61(2):111-6. PubMed ID: 1683718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombocytosis versus thrombocythemia--differential diagnosis of elevated platelet count].
    Thiele J; Kvasnicka HM
    Pathologe; 2000 Jan; 21(1):31-8. PubMed ID: 10663667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chronic myeloproliferative diseases].
    Sréter L
    Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.
    Phekoo KJ; Richards MA; Møller H; Schey SA;
    Haematologica; 2006 Oct; 91(10):1400-4. PubMed ID: 17018393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.
    Thiele J; Funke S; Holgado S; Choritz H; Georgii A
    Anal Quant Cytol; 1984 Sep; 6(3):155-67. PubMed ID: 6594964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.